以生物科技驱动健康营养变革 诺和新元携两大高端原研益生菌品牌亮相NHNE2025

Core Insights - The China International Health Nutrition Expo (NHNE) recently opened in Guangzhou, showcasing the flagship event for the Asian health nutrition and dietary supplement industry [1] - Novonesis, formed from the merger of Novozymes and Chr. Hansen, presented its two premium probiotic brands, PrecisionBiotics and Microbiome Labs, highlighting its research and innovation in the precision microbiome field [1][2] Industry Trends - National strategies such as "Healthy China 2030" and the "National Nutrition Plan (2017-2030)" are driving high-quality development in the nutrition and health industry, with increasing demand for functional nutrition products, particularly probiotics [2] - The growing public health awareness is accelerating the demand for functional nutrition products, positioning probiotics as a key pillar in the health industry [2] Company Developments - Novonesis is actively responding to national strategies by collaborating with industry partners to enhance research and education in original probiotic development, contributing to national health improvement [2] - At NHNE, the brand showcased a range of functional solutions from microbiome testing to symptom improvement, including its flagship products MegaSporeBiotic and TGR comprehensive gut repair solutions [2][3] - PrecisionBiotics presented its innovative products covering various health areas such as gut health, emotional health, immune health, and women's health, catering to specific consumer health needs [3] Strategic Partnerships - Novonesis deepened collaborations with platforms like JD Health and Tmall International to explore win-win models in localized applications, professional channel building, and user education [4] - The company participated in high-level forums during the expo, discussing topics like the implementation of microbiome research and trends in personalized nutrition, seeking new opportunities in the Chinese health nutrition market [3][4] Future Outlook - Novonesis plans to increase its research investment and strategic collaboration in the Chinese market, leveraging its probiotic brands to empower national health and contribute to a more professional and diversified health industry [6]